期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

难治性垂体腺瘤的治疗现状和展望 被引量：3

原文传递
导出
摘要 垂体腺瘤是发生在腺垂体的良性肿瘤，约占颅内肿瘤的10％，近年来有逐渐增加的趋势。系统的放射学检查和尸检结果显示，垂体腺瘤占普通人群的17％左右，且随着年龄的增加发病率逐渐上升。
作者 代从新 蔡锋 刘小海 马四海 姚勇 王任直
机构地区 中国医学科学院北京协和医院神经外科
出处 《中华神经外科杂志》 CSCD 北大核心 2012年第4期425-427,共3页 Chinese Journal of Neurosurgery
关键词 垂体腺瘤 难治性 治疗 放射学检查 良性肿瘤 颅内肿瘤 普通人群 腺垂体
分类号 R736.4 [医药卫生—肿瘤]
  • 相关文献

参考文献41

  • 1Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pit- uitary adenomas: a systematic review. Cancer, 2004, 101:613-619.
  • 2Vance ML. Treatment of patients with a pituitary adenoma: one clinician's experience. Neurosurg Focus ,2004,16 : El.
  • 3Li-Ng M, Sharma M. Invasive pituitary adenoma. J Clin Endocrinol Metab ,2008,93:3284-3285.
  • 4Zada G, Woodmansee WW, Ramkissoon S, et al. Atypical pit- uitary adenomas : incidence, clinical characteristics, and implications. J Neurosurg,2011,114 :336-344.
  • 5Aghi MK. Management of recurrent and refractory Cushing dise- ase. Nat Clin Pract Endocrinal Metab ,2008,4:560-568.
  • 6Wang RZ. [ Selection of treatment methods for pituitary aden- oma]. Zhonzhua Yi Xue Za Zhi.2006.86 : 1585-1588.
  • 7王任直,姚勇.垂体腺瘤的微创治疗[J].中国微侵袭神经外科杂志,2008,13(3):97-99. 被引量：7
  • 8Buchfelder M. Treatment of pituitary tumors: surgery. Endocr- ine ,2005,28:67-75.
  • 9Laws EJ. Pituitary pseudocapsule. J Neurosurg, 2006,104 : 1-2 ; discussion 2-3.
  • 10Lee E J, Ahn JY, Noh T, et al. Tumor tissue identification in the pseudocapsule of pituitary adenoma : should the pseudocapsule be removed for total resection of pituitary adenoma? Neurosurgery, 2009,64 ( 3 Suppl) : 62 -69 ; discussion 69 -70 .

二级参考文献8

  • 1Aghi MK. Management of recurrent and refractory Cushing dise- ase. Nat Clin Pract Endocrinol Metab,2008 ,4 :560-568.
  • 2Syro LV,Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer, 2011, 117 : 454-462.
  • 3Fadul CE,Kominsky AI,, Meyer LP, et al. Long-term response of pituitary carcinoma to temozolomide. Report of two eases. J Neurosurg ,2006,105:621-626.
  • 4McCormack AI, McDonald KL, Gill AJ, et al. Low O6-methylg- uanine-DNA methyltransferase(MGMT) expression and response to temozolomide in aggressive pituitary turnouts. Clin Endocrinol (Oxf) ,2009,71:226-233.
  • 5Kovacs K, Scheithauer BW, Lombardero M, et al. MGMT imm-unoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol,2008,115:261-262.
  • 6Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas:a French muhicenter experience. J Clin Endocrinol Metab, 2010, 95: 4592-4599.
  • 7Bush ZM, Longtine JA, Cunningham T, et al. Temozolomide trea- tment for aggressive pituitary tumors: correlation of clinical outcome with O ( 6 ) -methylguanine methyltransferase ( MGMT ) promoter methylation and expression. J Clin Endocrinol Metab, 2010,95 : E280-E290.
  • 8Morin E, Berthelet F, Weisnagel J, et al. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary, 2010. [ Epub ahead of print ].

共引文献13

同被引文献85

  • 1Melmed S. Mechanisms for pituitary tumorigenesis : the plastic pituitary[J]. J Clin Invest, 2003,112(11) :1 603-1 618.
  • 2Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pi- tuitary adenomas: a systematic review[J]. Cancer, 2004, 101 (3) :613-619.
  • 3Li-Ng M, Sharma M. Invasive pituitary adenoma[J]. J Clin Endocrinol Metab,2008,93(9):3 284-3 285.
  • 4Zada G, Woodmansee WW, Ramkissoon S, et al. Atypical pi- tuitary adenomas: incidence, clinical characteristics, and im- plications[J]. J Neurosurg,2011,114(2) :336-344.
  • 5Marucci G. Treatment of pituitary neoplasms with temozolo- mide: Areview[J]. Cancer,2011,117(17) :4101-4102.
  • 6Meeormack AI, Wass JA, Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MG- MTstatus[J]. EurJ ClinInvest,2011,41(10):1 133-1 148.
  • 7Mceormack AI, Mcdonald KL, Gill AJ, et' al. Low 06- methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours [J]. Clin Endocrinol (Oxf) ,2009,71(2):226-233.
  • 8Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolo- mide regimens: antitumor activity, toxicity, and immunomod- ulatory effects[J]. Cancer,2010,116(12) :2 868-2 877.
  • 9Reardon DA, Rich JN, Friedman HS, et al. Recent advances in the treatment of malignant astrocytoma[J].J Clin Oncol, 2006,24(8) :1 253-1 265.
  • 10Brandes AA, Basso U, Reni M, et al. First-line chemother- apy with cisplatin plus fractionated temozolomide in recurrent glioblastoma muttiforme: a phase II study of the Gruppo Ital- iano Cooperativo di Neuro-Oncologia[J]. J Clin Oncol,2004, 22(9) :1 598-1 604.

引证文献3

二级引证文献2

中华神经外科杂志
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部